According to results presented at the 2021 ASH Annual Meeting, the triplet combination of magrolimab plus azacitidine and venetoclax was safe, with high response rates reported in patients with newly diagnosed high-risk acute myeloid leukemia.
Evaluating the Magrolimab-Based Triplet Combination in High-Risk AML
By Naval Daver, MD - Last Updated: February 2, 2023Advertisement
Related Posts
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Clinical development of AUTX-703 is planned to begin in the first quarter of 2025.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
The amended protocol includes reducing the size of the MIRACLE trial by approximately 10%.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.